News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Michael Stek, MD

Articles by Michael Stek, MD

Quantitative and Cost Evaluation of Three Antiglaucoma Beta-Blocker Agents: Timoptic-XE7 versus Two Generic Levobunolol Products

ByDavid Hartenbaum, MD,Michael Stek, MD,Brian Haggert, MS,Dan Holder, PhD,John Earle, PhD,Alice Wysocki, MS,Bernard Schwartz, MD, PhD

February 1st 1996

Latest Updated Articles

Quantitative and Cost Evaluation of Three Antiglaucoma Beta-Blocker Agents: Timoptic-XE7 versus Two Generic Levobunolol Products
Published: February 1st 1996 | Updated:

Trending on AJMC

FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss

Sleep Apnea Risk Tied to 40% Higher Odds of Poor Mental Health

Top 5 Most-Read "5 Things" Articles of 2025

Top 5 Most-Read Vaccine Content in 2025

Baricitinib Shows Real-World Effectiveness in Severe Alopecia Areata Hair Loss

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.